The INSPIRE12 Business Awards ceremony attended by over 500 of Hampshires’ finest saw Nevasic awarded “Innovation of the Year” .

The award was presented by Thomas Thorp – Corporate Affairs Director at Lilly Pharmaceuticals (now Senior Director UK Corporate Affairs – Lilly Industries) in Basingstoke – who were also the category sponsors and members of the judging process.

Thom was later quoted by the Basingstoke Gazette saying “There were some really good nominations for this category this year, showing true innovation and things that will make a difference and these guys are clearly practising that.

They have the potential to become massive – it’s very exciting”.

This is the first occasion in our history that a “pharma” company has given us a thumbs up and its truly appreciated.

Dave & Jo From Nevasic Receive The “Inspire12 Innovation” Award.

This award comes hot on the heals of new clinical research data showing Nevasic in use with cancer patients. The positive nature of this data means more clinical trials are being scheduled.

DAVAL is the developer and manufacturer of an audio programme which stabilises the balance receptors in the inner ear in order to provide relief from nausea and sickness.

Relief for a variety of causes and conditions

Sufferers of Abdominal Migraine, Travel Sickness, Ménière’s Disease, Crohn’s Disease, Labyrinthitis, Migraine, Vertigo and even Radio and Chemotherapy treatment have used our product and reported benefits from reduced and even total relief from their symptoms. In a surprising and growing number of instances these reports are being passed to us from medical professionals in a variety of fields.

Nevasic Wins Prestigious Inspire12 Award

Researched and Studied

DAVAL products have been under study with the Winchester and Eastleigh NHS Trust – within their NHS Birth Centre at Andover. This study is produced outstanding results in stopping sickness known as “Morning Sickness” in pregnancy.
A full clinical trial has been completed with this product by the MRC Spatial Disorientation Group, Imperial College School of Medicine, London, United Kingdom.

Looking to the future

DAVAL products were put to a short pilot study at University College London (Carousel Ward and Teenage Cancer Trust Unit) and the Kent and Canterbury Hospital – within their Oncology wards where our product was supplied to Cancer patients after Radio and Chemotherapy treatment.
Indications were of a very positive nature and DAVAL welcomes the opportunity for further clinical trials.

We provide this site as a tool for telling the world about Nevasic. This site is not designed to be “the world’s repository” for medical information about the topic/s of nausea